Literature DB >> 6207423

1-beta-D-arabinosyl-5-azacytosine. Cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells.

R I Glazer, M C Knode.   

Abstract

The cytocidal activity of arabinosyl-5-azacytosine (araAC) and its effect on the synthesis and methylation of DNA in the human colon carcinoma cell line HT-29 was examined and compared with three other cytidine analogues. Treatment for 2 hr with 10(-6)M arabinosylcytosine (araC), araAC, 5-azacytidine (AZC), or 2'-deoxy-5-azacytidine (dAZC) produced a 7-30% reduction in cell viability. Prolongation of drug exposure to 24 hr significantly enhanced the cytotoxicity of all analogues, and particularly dAZC. AZC and dAZC were potent inhibitors of DNA methylation in the absence of inhibition of DNA synthesis, whereas araC and araAC primarily affected DNA synthesis. RNA synthesis was not affected by any of the analogues. dAZC and AZC were incorporated into DNA to a greater extent than were araC or araAC upon short- and long-term drug exposure, whereas only AZC was incorporated into RNA. These data indicate that araAC appears to behave more as an analogue of araC rather than of dAZC or AZC, wherein it produces rapid inhibition of DNA synthesis and is incorporated into DNA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207423

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study.

Authors:  J P Kuebler; B Metch; D E Schuller; M Keppen; H E Hynes
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

2.  A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study.

Authors:  G B Selby; C Upchurch; J Townsend; H J Eyre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors:  J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

4.  Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines.

Authors:  Aaron N Nguyen; Paul W Hollenbach; Normand Richard; Antonio Luna-Moran; Helen Brady; Carla Heise; Kyle J MacBeth
Journal:  Lung Cancer (Auckl)       Date:  2010-09-09

5.  Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.

Authors:  E S Casper; G K Schwartz; D P Kelsen
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

7.  Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study.

Authors:  S K Williamson; J J Crowley; R B Livingston; T J Panella; J W Goodwin
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

9.  2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

Authors:  J A Ellerhorst; P Frost; J L Abbruzzese; R A Newman; Y Chernajovsky
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells.

Authors:  Sunyoung Joo; Hyun Ju Lim; John D Jackson; Anthony Atala; James J Yoo
Journal:  J Tissue Eng       Date:  2014-02-18       Impact factor: 7.813

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.